| Year |
Citation |
Score |
| 2023 |
Ryu J, Barkal S, Yu T, Jankowiak M, Zhou Y, Francoeur M, Phan QV, Li Z, Tognon M, Brown L, Love MI, Lettre G, Ascher DB, Cassa CA, Sherwood RI, et al. Joint genotypic and phenotypic outcome modeling improves base editing variant effect quantification. Medrxiv : the Preprint Server For Health Sciences. PMID 37732177 DOI: 10.1101/2023.09.08.23295253 |
0.527 |
|
| 2023 |
Zhou Y, Pan Q, Pires DEV, Rodrigues CHM, Ascher DB. DDMut: predicting effects of mutations on protein stability using deep learning. Nucleic Acids Research. PMID 37283042 DOI: 10.1093/nar/gkad472 |
0.642 |
|
| 2022 |
Zhou Y, Al-Jarf R, Alavi A, Nguyen TB, Rodrigues CHM, Pires DEV, Ascher DB. kinCSM: Using graph-based signatures to predict small molecule CDK2 inhibitors. Protein Science : a Publication of the Protein Society. 31: e4453. PMID 36305769 DOI: 10.1002/pro.4453 |
0.489 |
|
| 2021 |
Zhao P, Zhuang L, Wang X, Huang S, Wu H, Zhou Y, Yan Y, Zhang F, Shen R, Li J, Liu S, Zhang R, Dong P, Mao Y, Fan Y, et al. Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers. European Journal of Medicinal Chemistry. 228: 114040. PMID 34906761 DOI: 10.1016/j.ejmech.2021.114040 |
0.34 |
|
| 2021 |
Jiang Z, Liao G, Yang Y, Lan Y, Xu L, Yan M, Zhou Y, Zhu J, Liu W, Bai J, Xiao Y, Li X. Analysis of Mutations and Dysregulated Pathways Unravels Carcinogenic Effect and Clinical Actionability of Mutational Processes. Frontiers in Cell and Developmental Biology. 9: 768981. PMID 34901014 DOI: 10.3389/fcell.2021.768981 |
0.301 |
|
| 2021 |
Zhou Y, Portelli S, Pat M, Rodrigues CHM, Nguyen TB, Pires DEV, Ascher DB. Structure-guided machine learning prediction of drug resistance mutations in Abelson 1 kinase. Computational and Structural Biotechnology Journal. 19: 5381-5391. PMID 34667533 DOI: 10.1016/j.csbj.2021.09.016 |
0.684 |
|
| Show low-probability matches. |